Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) 
Introduction

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), such as gefitinib or erlotinib, is mainly metabolized in the liver. To date, the safety data on administering EGFR-TKI to patients with liver dysfunction is quite limited. Here, we administered gefitinib to two patients with adenocarcinoma of the lung with liver cirrhosis, and analyzed pharmacokinetics (PK).
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